secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2021-07-13T23:59:59+00:00
Accession:  0001683168-21-002921
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M
--------------------------------------------------------------------------------

- Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.
- Authorized shares decreased from 50B to 33,333,334; par value unchanged at $0.0001.
- Effective July 12, 2021; temporary ticker PMCBD for 20 business days, then revert to PMCB.
- CEO states split is a necessary step before Nasdaq listing and to support financing.
- No fractional shares issued; proportionate voting power unaffected; rounding up to whole share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/0001683168-21-002921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-002921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer